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Background. General practitioners (GPs) as a group have been identified as playing an important role in gonorrhoea management
in Flanders. Belgian guidelines recommended ceftriaxone or alternatively spectinomycin from 2008 onwards and azithromycin
combination therapy since 2012.Objectives. This study investigates to which extent contemporary gonorrhoea treatment guidelines
were followed.Methods. A retrospective cohort study (2009–2013) of antibiotic prescriptions for gonorrhoea cases registered in the
Flemish Intego general practice database was carried out. The database is based on electronic health record routine registration by
over 90 GPs using the software programme Medidoc. Results. Ninety-one gonorrhoea cases with ten chlamydia and one genital
trichomonas coinfections in 90 patients were registered between 2009 and 2013. The proportion of cases with ceftriaxone and/or
spectinomycin prescriptions rose from 13% (two of 15 cases) in 2009 to 56% (nine of 16 cases) in 2013. Combination therapy of
ceftriaxone and/or spectinomycin together with azithromycin rose from 0 of 15 cases (0%) in 2009 to 7 of 16 cases (44%) in 2013.
Conclusion. Although numbers are small, the results suggest that gonorrhoea therapy guideline adherence improved between 2009
and 2013.
1. Introduction
As in other parts of Europe [1, pp. 19-20], the number of newly
diagnosed gonorrhoea cases has been increasing in Flanders
since 2009 [2, p. 26]. Figures from the Flemish Agency for
Care and Health [3] show an increase from 622 gonorrhoea
cases in 2009 to 1162 cases in 2013 [4]. That year, the Flemish
Minister of Health confirmed the need to reinforce measures
against sexually transmitted infections (STIs) [5].
No comprehensive surveillance system for gonorrhoea
exists in Belgium. Instead, the following complementary
surveillance systems exist: first, the Belgian Network of
Sentinel Laboratories forMicrobiology [6, p. 15] covers about
50% of diagnostic activity [2, p. 6]; the Belgian Network
of Sentinel STI Clinics/Clinicians in cooperation with the
Belgian Network of Sentinel General Practices records STI
cases including risk determinants and behaviour [6, pp.
16–18]; and finally, gonorrhoea is subject to mandatory
notification to the Agency for Care and Health in Flanders
[7] and to the respective health authorities in the Brussels-
Capital Region [8, p. 11]. The case definition for mandatory
notification of gonorrhoea [9, p. 49] subsumes probable cases
(clinically suspected, after recent sexual contact with con-
firmed case) and confirmed cases (clinically compatible with
laboratory confirmation, namely culture of N. gonorrhoeae,
antigen test or PCR).
The World Health Organization recommends avoidance
of an antibiotic when a 5% resistance is reached [10, p. 14] and
points out that multidrug resistance of gonorrhoea strains
against antibiotics constitutes a growing public health threat
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Table 1: Number of annually participating general practitioners (GPs), patient population, annual number of gonorrhoea cases per
participating GP, and annual number of bacterial/protozoal coinfections, Intego database, 2009–2013.
Year 2009 2010 2011 2012 2013 Total
Number of participating GPs 111 116 109 105 98
Patient population 159698 156068 166740 137796 141631
Number of gonorrhoea cases 15 22 17 21 16 91
Coinfections of chlamydia 1 2 4 3 0 10
Coinfections of genital trichomonas 0 0 0 0 1 1
Coinfections of syphilis 0 0 0 0 0 0
[11, 12]. In 2009, the Belgian National Reference Labora-
tory for Neisseria gonorrhoeae found Neisseria gonorrhoeae
resistance against penicillin, tetracycline, and ciprofloxacin
in 35.5%, 48.0%, and 57.5% of the strains, respectively [13,
p. 39]. “Resistance against azithromycin decreased from 3.1%
in 2007 to 1.6% in 2008. All strains were susceptible to
ceftriaxone and spectinomycin” [13, p. 39].
Changing resistance patterns of gonococci led to the
adaptation of respective national guidelines. From 2008
onwards, the Belgian Antibiotic Policy Coordination Com-
mittee (BAPCOC) recommended the cephalosporin ceftriax-
one as first choice or the aminoglycoside spectinomycin for
eradication of gonococci instead of a quinolone (ofloxacin,
ciprofloxacin, and levofloxacin) ([14, p. 53, p. 58]; [15, p.
7, p. 62]; [16, p. 60]). In 2008, BAPCOC recommended
azithromycin or doxycycline for etiological treatment of
chlamydia [15, p. 62] and in combination with ceftriaxone for
empirical treatment of urethritis [15, p. 62]. In 2012, BAPCOC
gave azithromycin a more prominent place for eradication
of gonococci as part of a combination therapy together with
ceftriaxone or spectinomycin [16, p. 60].
BAPCOCdid not rule out entirely other antibiotic classes:
quinolones remained for gonococcal urethritis if sensitivity
was proven ([15, p. 62]; [16, p. 60]). In 2008, BAPCOC
continued to recommend ofloxacin and levofloxacin as
empiric treatment for prostatitis and orchiepididymitis, with
ceftriaxone to be added if gonococci were suspected [15,
p. 54-55]. In 2012, the first choice for prostatitis in case of
suspected gonococci became ceftriaxone or spectinomycin
with azithromycin [16, p. 52] and ceftriaxone or spectino-
mycin with doxycycline for orchiepididymitis in case of a
suspected STI [16, p. 53]. BAPCOC recommended amox-
icillin with clavulanic acid or cotrimoxazole for prostatitis
and amoxicillin with clavulanic acid or cefuroxime axetil for
orchiepididymitis as alternative or second choice ([15, p. 54-
55]; [16, p. 52-53]).
The Flemish gonorrhoea treatment guidelines (October
2009) [17] followed BAPCOC and ceftriaxone or spectino-
mycin as treatment of choice for gonorrhoea eradication and
to combine azithromycin for chlamydia [17, p. 215]. In May
2013, the recommendation of combination therapy of ceftri-
axone or spectinomycin with azithromycin for gonorrhoea
followed [18].
Laisnez and colleagues found in 2010 that the general
practitioner (GP) in the provinces of East and West Flanders
was the treating physician in 79.1% of gonorrhoea cases
[19, p. 5] and that 55.7% of GPs adhered to current guidelines,
defined as treatment with ceftriaxone and/or spectinomycin,
whereas GPs prescribed ciprofloxacin in 28.7% of cases
[19, p. 5]. Aside from this study and their follow-up study
for 2012–2014 [20], knowledge about antibiotic gonorrhoea
treatment choices in general practice in Flanders is limited.
Therefore, this study investigates (a) which antibiotics for
gonorrhoea treatment were registered in the Intego general
practice database for 2009–2013 and (b) to which extent
Belgian/Flemish gonorrhoea treatment guidelines were fol-
lowed.
2. Methods
2.1. Setting. The Flemish Intego network (for details see
Truyers et al. [21], Truyers et al. [22], and Vaes et al. [23])
is “the only operational computerized morbidity registration
network in Belgium based on general practice data” [21, p. 1].
Over 90 IntegoGPs (see Table 1), who are good coders, collect
data on about 2% “of the Flemish population representative
in terms of age and sex” [21, p. 1]. “Intego procedures were
approved by the ethical review board of the Medical School
of the Catholic University of Leuven (N∘ML 1723) and by the
Belgian Privacy Commission (number SCSZG/13/079)” [23,
p. 10].
All Intego GPs work with the proprietary software pro-
gramme Medidoc. GPs routinely register all new diagnoses
and new drug prescriptions which are collected together
with patient information from GPs’ personal computers
and entered into a central database [23, p. 2]. There is
no interference with the daily work of the GP [22, p.
16]. GPs are requested to encode clinical labels (keywords)
offered by the software programme.The classification system
is proprietary: to each clinical label (keyword) Medidoc
assigns a programme-specific internal Medidoc code and
a “diagnostic group” code, for example, for gonorrhoea,
syphilis, trichomonas, and chlamydia. Furthermore, it links
new diagnoses to the International Classification of Primary
Care (ICPC-2) and the International Statistical Classification
of Diseases and Related Health Problems, 10th Revision
(ICD-10) [23, p. 2].
2.2. Study Design. In order to investigate antibiotic treatment
choices after the publication of the 2008 BAPCOC recom-
mendations, this retrospective cohort study used Intego data
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of a 5-year period from 1 January 2009 to 31 December 2013.
The population of interest was constituted by the practice
population, calculated from the yearly contact group plus the
group which did not visit their general practitioner in a given
period (method: see [24]).
We selected the relevant Medidoc codes for gonorrhoea,
urogenital Chlamydia trachomatis infections, syphilis, and
genital trichomoniasis together with the diagnostic group
variable representing these four STIs (see Supplementary
File, Annex 1, in Supplementary Material available online
at https://doi.org/10.1155/2017/1860542). Observations with
these codes were extracted together with the patient number
and the beginning date of the respective diagnosis.The num-
ber of gonorrhoea infections per yearwas counted as episodes
(cases), consisting of one ormore patient consultations for the
same medical diagnosis.
In the scientific literature, there are various approaches
to define the interval distinguishing a new from an ongoing
genital chlamydia or gonorrhoea episode (or STI episodes
in general) in a database. Regarding the Belgian Network
of Sentinel Laboratories for Microbiology, an interval of
more than 90 days between two positive chlamydia or
gonorrhoea results was defined before a second positive result
was counted as a new episode [2, p. 6]. In their article
on genital Chlamydia trachomatis infections, Hughes and
colleagues stated that “events occurring within 30 days of
each other formed part of the same test, diagnosis, treatment,
or referral episode” [25, p. 311]. Subsequently, “all events
occurring within 30 days of each other were grouped as
a single episode,” and an alternative episode definition of
60 days “was found to have negligible impact on incidence
estimates” [25, p. 311]. In their study on STIs in sexual health
clinics in England, Mohammed and colleagues counted only
1 diagnosis of each STI within a 6-week period [26, p.
88]. For their “Comparison of STI-Related Consultations
among Ethnic Groups in the Netherlands,” Woestenberg and
colleagues [27] used the application EPICON “that groups
consultations with similar ICPC-codes occurring less than
two months apart” ([27, p. 2]; [28]). Following the example
of Suijkerbuijk and colleagues on Chlamydia trachomatis
infections diagnosed by GPs in the Netherlands [29, p. 3],
we counted a second episode with the same diagnosis for the
same patient as a new case only after an interval of at least
twomonths after the beginning date of the first diagnosis.We
defined the two month-interval as 62 days.
Observations of chlamydia, syphilis, and genital tri-
chomonas were kept only if they concerned gonorrhoea coin-
fections. We compared two definitions of “coinfection”: we
took the “date of beginning of diagnosis” of the gonorrhoea
infection as point of origin. According to Definition 1, a
registration of a Chlamydia trachomatis, syphilis, or genital
trichomonas infection was counted as coinfection if it was
registered with its “day of beginning of diagnosis” during
an interval of up to seven days before/after the gonorrhoea
“date of beginning of diagnosis.” According to Definition
2, the interval of 7 days was replaced by an interval of
14 days before/after the “day of beginning of diagnosis” of
the gonorrhoea infection. Applying the 14-day period led
to the detection of one further chlamydia infection. The
patient had been prescribed erythromycin at the gonorrhoea
infection registration date, and 12 days later doxycycline,
when chlamydia was registered.We decided that the case was
congruent with a coinfection and kept the latter definition.
For one patient, two gonorrhoea cases were recorded,
but only for the second case antibiotic therapy was recorded.
Subsequently, the patient number for the first case was
changed in order to obtain a set of unique patient numbers in
the first file. Based on the patient number, the file wasmerged
with a second one containing year of birth and sex. For the
patientwhose patient number had been changed, year of birth
and sex were added manually.
Then we selected ATC group codes (Anatomical Thera-
peutic Chemical Classification System, for details, see [30])
of the anti-infectives (see Supplementary File, Annex 2) and
extracted matching observations together with the patient
number, the name of the prescribed medication, and the
prescription date. Subsequently, the data file wasmergedwith
the previous one based on the patient number.
Dermatological and sensory antibiotics (with ATC codes
beginning with D and S) were not included in the analysis.
If the same antibiotic (defined as antibiotic with the same
ATC code) was given more than once in the period fourteen
days before until fourteen days after the beginning date of
gonorrhoea diagnosis, then this was counted as therapy with
one antibiotic.Thus, we obtained theATP codes prescribed in
a close temporal context of each recorded gonorrhoea case.
We had to determine the period of time between regis-
tration date of the beginning of gonorrhoea diagnosis and
registration date of the antibiotic judged as sufficient to cover
empiric therapy, based on symptoms suspecting venereal
disease without having a PCR or culture result, as well as
possibly changing therapeutic choices after obtaining the
positive laboratory result after the patient consultation.
Since this was the first investigation into gonorrhoea
therapy based on Intego data, we compared two time spans:
the first covered antibiotics registered within one week
before/after the beginning date of the gonorrhoea diagnosis
and the second two weeks.
By enlarging the period to 14 days before/after the gon-
orrhoea registration date, 8 additional antibiotics (excluding
the same antibiotic prescribed within 7 days and again
within the 14-day period) were found: azithromycin twice,
doxycycline twice, ciprofloxacin twice, moxifloxacin once,
andmetronidazole once. One additional antibiotic was found
in six cases and two in one case. Since it concerned antibiotics
expected for the therapy of sexually transmitted infections,
we kept the larger interval.
We grouped the cases according to number and combi-
nation of ATP codes prescribed. Combination therapy was
defined as prescription of two or more systemic antibiotics
with different ATC codes within the period fourteen days
before until fourteen days after the beginning date of a
gonorrhoea diagnosis.
Due to the protection of patient privacy, we had obtained
the year of birth, but not the birth date of the respective
patients. In order to keep the error of the age estimation
within half a year or less, we assigned July 1 of the birth year as
fictitious birthday and estimated the age as the difference of
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Table 2: Age class and sex distribution of gonorrhoea cases (𝑛 = 91), Intego database, 2009–2013.
Age class Male % of males Female % of females Total
1 (<15 years) 0 0% 0 0% 0
2 (15–24 years) 17 22% 6 40% 23
3 (25–44 years) 43 57% 4 27% 47
4 (45+ years) 16 21% 5 33% 21
Total 76 100% 15 100% 91
the recorded beginning date of the gonorrhoea diagnosis and
the fictitious birthday.We chose four age classes, namely, 0–14
years, 15–24 years, 25–44 years, and 45+ years. Descriptive
analysis was performed with STATA 12.0 (StataCorp, Texas)
and Excel 2010.
3. Results
3.1. Annual Frequency of Gonorrhoea Cases per GP. During
the observation period 2009–2013, between 98 (minimum)
and 116 GPs (maximum) participated annually, observing an
annual patient population fluctuating around an order of
magnitude of 150,000 (see Table 1). In total, 91 gonorrhoea
cases were registered, including two cases referring to the
same patient, one in November 2012 and one in April 2013.
No observation was excluded for being registered a second
time in less than 2 months. In 11 cases, bacterial/protozoal
gonorrhoea coinfections were registered, namely, chlamydia
ten times and genital trichomonas once. No syphilis coinfec-
tion was recorded.
3.2. Age and Sex Distribution. The 91 gonorrhoea cases
included 76males and 15 female cases, thus a ratio of males to
females of 5/1. There were no cases under the age of 15 years.
43 of 76 male cases (57%) belonged to the age class 25–44
years, whereas the female cases were quite evenly spread
among the age classes 15–24 years (6 cases, 40%), 25–44 years
(4 cases, 27%), and 45+ years (5 cases, 33%). The age and sex
distribution is shown in Table 2 (see also [31]).
3.3. Prescribed Antibiotics. In 78 of the 91 cases (86%),
systemic antibiotic therapy was recorded. Antibiotics with 16
different ATC codes were prescribed.
In 35 cases (38%), one antibiotic was recorded, most often
a quinolone (12 cases), a penicillin derivative (amoxicillin
with/without enzyme inhibitor clavulanic acid, flucloxacillin,
seven cases), or ceftriaxone (six cases). In 33 cases (36%),
two different antibiotics were recorded in 18 different ATC
code combinations,most often ceftriaxonewith azithromycin
(nine cases). In ten cases (11%), three or more different
antibiotics were prescribed. In general, combination thera-
pies which included penicillin derivatives played a minor
role with five cases, including one combination therapy
with spectinomycin, one with azithromycin, and none with
ceftriaxone. An overview is given in Table 3.
Cases with coinfections showed a wide variety of ther-
apeutic choices. For three of the ten gonorrhoea-chlamydia
coinfections, only one antibiotic (ciprofloxacin in 2010, doxy-
cycline in 2011, and azithromycin in 2012, resp.) was recorded.
In total, six of the ten gonorrhoea-chlamydia coinfections
received azithromycin prescriptions. Four of the gonorrhoea-
chlamydia coinfections were treated with ceftriaxone and/or
spectinomycin together with azithromycin, all from 2011
onwards. The single gonorrhoea/trichomonas coinfection in
2013 was treated with azithromycin and metronidazole.
Contrary to male gonorrhoea cases which showed a
wide spectrum of therapeutic choices, all 11 female cases
with registered anti-infective therapy were treated with either
amoxicillin alone (3 cases), ceftriaxone alone (4 cases), a
combination of ceftriaxone and azithromycinwith or without
a third anti-infective (3 cases), or azithromycin with metron-
idazole (1 case, gonorrhoea-trichomonas coinfection). No
spectinomycin, no quinolone, and no doxycycline were reg-
istered in female cases. No clustering of age classes regarding
antibiotic prescriptions could be detected.
3.4. Prescription of Quinolones. The number of cases with
quinolone therapy decreased continuously from 11 of 15
cases (73%) in 2009 to two of 16 cases (13%) in 2013.
Combination therapy of a quinolone with ceftriaxone and/or
spectinomycin was recorded for one case each year except
in 2011 (three cases). In eight cases, the therapy included
quinolone(s) and doxycycline (five cases in 2009, one in 2010,
and two in 2012).
3.5. Prescription of Cephalosporins and/or Spectinomycin and
Their Combination with Azithromycin. The proportion of
ceftriaxone and/or spectinomycin prescriptions increased
continuously throughout the observation period: the number
of cases with prescription of ceftriaxone rose from 0 of
15 cases (0%) in 2009 to nine of 16 cases (56%) in 2013,
while spectinomycin was prescribed twice in 2009, reached
a peak of four cases in 2012, and was not recorded in
2013. Thus, the annual number of cases with prescription
of ceftriaxone and/or spectinomycin rose from two of 15
(13%) in 2009 to nine of 16 cases (56%) in 2013. Cases with
combination therapy of ceftriaxone and/or spectinomycin
with azithromycin rose from 0 of 15 cases (0%) in 2009 to
seven of 16 cases (44%) in 2013 (see Table 4).
Cephalosporins other than ceftriaxone were prescribed
three times, cefuroxime with ciprofloxacin once in 2009,
cefotaxime with doxycycline and azithromycin once in 2012,
and cefuroxime alone once in 2013, bringing the number of
cases with a cephalosporin prescription in 2013 up to ten of
16 cases (63%).
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Table 4: Prescription of ceftriaxone, spectinomycin, and/or azithromycin for gonorrhoea cases registered in Flemish general practice
2009–2013 (𝑛 = 91), Intego database; in brackets (): number of cases with chlamydia coinfection; in double brackets (()): number of cases
with genital trichomonas coinfection.
2009 2009 (%) 2010 2010 (%) 2011 2011 (%) 2012 2012 (%) 2013 2013 (%) Total
Total number of
gonorrhoea
cases recorded
15 (1) 22 (2) 17 (4) 21 (3) 16((1))
91
(10)
((1))
No antibiotic
recorded 1 7% 5 23% 0 0% 4 19% 3 19% 13
Prescribed
antibiotic(s)
include
Ceftriaxone 0 0% 3 14% 6 (2) 35% 6 (2) 29% 9 56% 24 (4)
Spectinomycin 2 (1) 13% 1 5% 2 (1) 12% 4 19% 0 0% 9 (2)
Ceftriaxone and
spectinomycin 0 0% 0 0% 1 (1) 6% 1 5% 0 0% 2 (1)
Ceftriaxone
and/or
spectinomycin
2 (1) 13% 4 18% 7 (2) 41% 9 (2) 43% 9 56% 31 (5)
Azithromycin 2 13% 2 9% 6 (3) 35% 7 (3) 33% 10((1)) 63%
27 (6)
((1))
Ceftriaxone
and/or
spectinomycin
together with
azithromycin
0 0% 1 5% 3 (2) 18% 4 (2) 19% 7 44% 15 (4)
4. Discussion
4.1. Defining a Proxy forGonorrhoeaTherapyGuidelineAdher-
ence. This study gives new insight into antibiotic prescrip-
tions for gonorrhoea therapy recorded in general medicine
in Flanders, notably the variety of treatment choices involved.
They are based on routine registration of physicians and thus
without the bias of GPs paying special attention to either
gonorrhoea or STI therapy.
Given the fact that ceftriaxone and spectinomycin were
recommended throughout the observation period, that
azithromycin was recommended formally since 2012/2013,
and that it takes time to spread the new version of a
guideline, the best proxy for gonorrhoea guideline adherence
2009–2012 seems to be the prescription of ceftriaxone and/or
spectinomycin, with 2013 being a transition year, and from
2014 onward the combination therapy of ceftriaxone and/or
spectinomycin together with azithromycin.
4.2. Gonorrhoea Cases without Recorded Treatment. For one-
seventh of gonorrhoea cases (13 of 91), no treatment is
recorded. Due to privacy protection procedures, the research
team at the Academic Center of General Practice of KU
Leuven is blinded to the GPs’ origin. It cannot be ruled out
that the patient was diagnosed but not treated (e.g., was not
treated empirically and did not show up any more after the
diagnosis arrived). However, it is more likely that the patient
was treated but the prescription of the antibiotic was not
registered. One possibility is that the GP did not register the
prescribed antibiotic within the period of 14 days before/after
the beginning date of the gonorrhoea diagnosis. Another
possibility is that the patient was treated by the specialist
or another health care provider and that the GP, notified by
the health care provider, registered the diagnosis but not the
treatment.
4.3. Proportion of Female Cases and Prescriptions for Female
Gonorrhoea Patients. The proportion of male (83.5%) and
female (16.5%) gonorrhoea cases in this study is comparable
with the ones found by Laisnez and colleagues in 2010
(81.7%men, 18.3%women) and 2012–2014 (79.0%men, 21.0%
women) [20, p. 19].
The absence of quinolones and doxycycline in female
gonorrhoea treatment may be due to several factors: (1) two-
thirds of cases (10 of 15) occurred in 2012 and 2013, with
ceftriaxone having been recommended as treatment of choice
for several years; (2) ceftriaxone, azithromycin, and amoxi-
cillin are considered safe/probably safe drugs in pregnancy
so that they can be prescribed easily even if pregnancy is
not ruled out, whereas quinolones and doxycycline are less
recommended during pregnancy [32, 33]; (3) possibly, there
is a clustering of few Intego GPs consulted by these women
leading to little variation in treatment choices.
4.4. Guideline Adherence according to the Intego Database.
Although the figures are small, the data suggest that gonor-
rhoea therapy guideline adherence improved between 2009
and 2013. After the Belgian BAPCOC guideline recommen-
dations of 2008, it took five years, until 2013, before more
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than half of Intego-registered gonorrhoea cases were treated
according to these guidelines, defined as prescription of
ceftriaxone and/or spectinomycin.
We do not know whether a combination therapy of
ceftriaxone or spectinomycin together with azithromycin
after publication of the new guidelines in 2012/2013 was
due to knowledge of the new guidelines or a therapeutic
choice which was based on previous recommendations and
aiming at covering a (potential) chlamydia infection as well.
We interpret the choice of ceftriaxone or spectinomycin,
both intramuscular drugs, instead of an oral antibiotic as a
strong hint that at least the recommendations of 2008 were
known.
As expected, it took time for the 2008 guideline to be
implemented in general practice. For 2010, recorded gonor-
rhoea therapy guideline adherence of Intego GPs was only
18%. Even if we assume that Intego cases without recorded
therapy are referred or reported cases, for which the GP did
not record the therapy, guideline adherence of Intego GPs
in 2010 was only 24% (4 of 17 cases). This figure is much
lower than the one for GPs in the study of Laisnez and
colleagues for 2010 in the provinces East and West Flanders
(55.7%). Sending the treatment guidelines to the treating
physician might have had a positive influence on guideline
adherence. The follow-up study of Laisnez and colleagues
showed 65.3% guideline adherence (defined as ceftriaxone
and/or spectinomycin) for 2012 and 53.0% new guideline
adherence (defined as ceftriaxone and/or spectinomycin
together with azithromycin) in 2013-2014 for all cases with
known treatment [20, p. 21] (not onlyGPs; separate figures for
GPswere not published, but theGPwas the treating physician
in 79.8% of cases [20, p. 19]).
These results are slightly higher than Intego figures for
2012 and about equal in 2013 if only cases with recorded
therapy are taken into account: 53% (9 of 17) of cases in
2012 (ceftriaxone and/or spectinomycin) and 54% (7 of 13)
of cases in 2013 (ceftriaxone and/or spectinomycin together
with azithromycin).
We assume that Intego figures of Table 4 on the propor-
tion of cases treated according to contemporary guidelines
represent the lower limit of cases treated according to con-
temporary guidelines by IntegoGPs.Given that gonorrhoea is
not a frequently encountered disease for the GP, gonorrhoea
therapy guideline adherence in 43% of cases in 2012 (pre-
scription of ceftriaxone and/or spectinomycin) and in 44%
of cases in 2013 (combination therapy with azithromycin, if
applying the new guidelines of 2012/2013) already constitutes
a considerable achievement. In the same year, a much more
common condition, the proportion of adult diabetics, aged
50+, under oral antidiabetics only, with appropriate follow-
up in Flanders ranged with 43.5% in the same order of
magnitude [34, p. 27].
Moderate guideline adherence has also been found in
other European settings. In general practice in England, less
than half of GP-treated episodes received a recommended
gonorrhoea regimen over the study period 2000–2011 [35,
p. 6-7]. Falchi and colleagues found in 2008 that slightly
more than 40% of responding sentinel GPs in France
fully completing the vignette prescribed two recommended
antibiotics or one recommended antibiotic against gonor-
rhoea [36, p. 3]. Since only 35% of GPs responded to a
fictitious case of chlamydia-gonorrhoea coinfection instead
of actual treatment choices in practice, the proportion of
French sentinel GPs treating with one ormore recommended
antibiotics may or may not have been substantially higher
than in the Intego network one year later.
Overall, Intego data confirm the dilemma pointed out
by Laisnez et al. ([19, p. 6]) that GPs in Flanders rarely
see gonorrhoea cases in their routine practice, but that they
as a group are important for the fight against gonorrhoea.
Furthermore, Vandenbruaene and Crucitti have shown that
the issue is not only knowing the latest guidelines, but also
the variety of them and their updates, since one of the
other guidelines recommended ciprofloxacin still in 2013 [37,
slides 55–58]. According to Boffin and colleagues, “time has
come for a general practice guideline on STI management,
including recommendations on HIV testing and discussing
of partner notification” [38, p. 7]. Preparation is under
way: the Belgian Health Care Knowledge Centre (KCE)
plans a “Guideline on Sexually Transmitted Diseases” study
[39].
4.5. Low Number of Overall Gonorrhoea Cases. More than 90
Intego GPs reported a total of 91 cases in 5 years, as a mean
less than 1 case per GP in 5 years. Elsewhere, we argued that
there seems to be not much underreporting of gonorrhoea
cases to mandatory notification in Flanders and that Intego
figures suggest GP involvement in most gonorrhoea cases
[31]. Another issue is that many infections may not have been
detected. According to Domus Medica, the association of
Flemish GPs which represents their interests and supports
them scientifically [40], few STIs are diagnosed by GPs in
comparison to other professions, although the GP quite often
is the first contact person [41]. In this context, a STI teaching
module for GPs has been developed, serving as a guide to
improve quality of care [42, 43]. Researchers from the Belgian
Scientific Institute of Public Health have also recommended
trainingGPs in STI consulting and in opportunistic screening
with risk factor awareness [44].
4.6. Limitations of the Study. The reasoning that there is
a link between gonorrhoea diagnosis and antibiotics pre-
scribed is based on the proximity of the registration dates
without an established link in the data. However, in 2008
and 2012, BAPCOC recommended ceftriaxone for few other
indications in ambulatory care other than genitourinary and
sexually transmitted infections which could be caused by N.
gonorrhoeae (syphilis in case of penicillin allergy ([15, p. 64];
[16, p. 62]) and carriers/prophylaxis of meningococci ([15, p.
74]; [16, pp. 70-71])), and spectinomycin was recommended
only for gonococci. Furthermore, they are intramuscular
drugs and therefore less comfortable to administer than
oral treatment. Azithromycin is more broadly indicated,
including respiratory, urogenital, dermal, and other bacterial
infections ([15, 16, 45]). We do not know whether or not a
registered antibiotic might have been prescribed for another
concomitant infection at the same time.
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In the Intego network, GP judgement is pivotal for
registering a gonorrhoea clinical label leading to a gon-
orrhoea diagnostic group Medidoc code. Underregistration
cannot be excluded, although Intego takes pains to recruit
proven good coders. We do not know whether the GP based
his/her judgement on laboratory and/or microscopy results,
as recommended in the guidelines, or whether it concerned
empiric or partner therapy. In case of prescription according
to the guidelines, they may even have been sent to the GP
by the Flemish health authorities in the course of mandatory
notification. Some patients with a negative test result may
have been treated presumptively, and these were not included
in our analyses. Correct dosages or the number of days to take
the medication could not be controlled.
The variable “date of beginning of diagnosis” may refer
to the date of first patient symptoms, the date of patient
consultation, or the date when the laboratory confirmation
of gonorrhoea arrived, so that it cannot be established
with certainty whether the antibiotic was prescribed before
knowledge about the etiology was attained.
At present, the generalisability of the findings to GPs
of all Flanders is not known. Intego is representative of the
Flemish population, but we do not knowwhether gonorrhoea
treatment choices (as well as STI detection strategies and
cooperation with specialists) of Intego GPs are representative
of all GPs in Flanders. Truyers and her colleagues at the Aca-
demic Center of General Practice at the Catholic University
of Leuven assume that Intego GPs probably only differ from
their colleagues in their handling of medical software but not
in their medical interventions or the composition of their
patients [22, p. 15]. However, given the fact that Intego GPs
are good coders and accept that their data are extracted, we
can assume as well that they are more than average devoted
to their professional duties andmore dedicated to implement
new guidelines into their daily routine. The percentage of
gonorrhoea treatment choices not according to guidelines
in Flanders may therefore rather be larger than smaller
compared with the one registered in Intego.
4.7. Opportunities for Future Research. The Intego database
itself will be developed further. For the moment, Intego
is planning a change in the registration software system
in order to take advantage of the modern possibilities in
electronic data-capture and transfer, enabled by the national
eHealth Roadmap [46]. This step will open new ways and
opportunities for surveillance and monitoring of diseases.
Furthermore, the extraction of antibiotic prescriptions for
gonorrhoea could be repeated annually, as soon as the data
from the respective year become available. Finally, Flemish
GPs with electronic health records other thanMedidoc could
be requested to send their STI data, if this is technically
feasible, in order to examine the generalisability of Intego to
all Flanders.
5. Conclusion
Given the global threat of antimicrobial resistance and sub-
stantial GP involvement in gonorrhoea control in Flanders,
monitoring GPs’ therapeutic choices including adherence to
national treatment guidelines remains important, especially
if monitoring is possible from routine registration. Data
from the Intego database give insight into the variation of
gonorrhoea treatment options registered by GPs in Flan-
ders during the observation period 2009–2013. Although
limited by small numbers, they suggest a gradual increase
of antibiotic prescriptions according to gonorrhoea guide-
lines. The Intego database offers a tool in place for annual
monitoring of general practitioners’ therapeutic choices to
treat gonorrhoea. Further research is necessary in order to
determine whether the Intego database offers a suitable proxy
for monitoring Intego GP gonorrhoea therapy guideline
adherence, with indicators ceftriaxone/spectinomycin and
azithromycin included in the prescription within 14 days
before/after the registered beginning date of gonorrhoea.
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